Esperion Therapeutics, Inc.ESPR released an update on the design and timing of a planned phase III program on its lead candidate, ETC 1002, following an end of phase II meeting with the FDA. The company’s shares tanked 47.8% following
Forex – financial instrument.Forex news
Esperion Therapeutics, Inc.ESPR released an update on the design and timing of a planned phase III program on its lead candidate, ETC 1002, following an end of phase II meeting with the FDA. The company’s shares tanked 47.8% following